LA BioMed Launches Commercialization Accelerator Program™ Powered by Larta Institute

public://2017-06/cap-image.png

Offers Additional Resources to Help its Startups Succeed

LOS ANGELES – (June 16, 2017) – LA BioMed is launching a Commercialization Accelerator Program™ (CAP), designed and implemented by Larta Institute, that will offer LA BioMed’s early stage bioscience companies additional resources to strengthen and speed their innovations to the marketplace, Keith B. Hoffman, PhD, LA BioMed vice president of business development and technology transfer, and Rohit Shukla,  Larta Institute CEO, announced today.

LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

public://2017-06/Dr-Edwards-IMG_7248-1366x672.png
Receives the Rhoda Benham Award from Medical Mycology Society

LA BioMed Sells Royalty Rights to Kybella®

public://2017-06/before-and-after-Kybella-crop.png

Proceeds to Help Fund Institute’s Groundbreaking Research and New Facilities

LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers. Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.